ABBOTT LABORATORIES (ABT)

Sentiment-Signal

7,9
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
28.3
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Kritische 8-K Meldungen

WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (27.04.2026)
DatumMeldungSchwereFilingAuszug
27.04.2026Item 5.02 — Abgang SchlüsselpersonenHOCHSEC      Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp
12.12.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co
01.05.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co
15.11.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co
01.05.2024Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co
12.06.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
21.10.2022Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co
15.09.2022Item 5.02 — Abgang SchlüsselpersonenHOCHSEC         Item 5.02              Departure of Directors or Certain Officers; Election of Directors; Appointment of Certai
13.12.2021Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02               Departure of Directors or Certain Officers; Election of Directors; Appointment of Certai
10.12.2021Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co
01.09.2021Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02            Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O
19.02.2021Item 5.02 — Abgang SchlüsselpersonenHOCHSEC          Item 5.02       Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offi
20.11.2020Item 5.02 — Abgang SchlüsselpersonenHOCHSEC          Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
27.02.2020Item 5.02 — Abgang SchlüsselpersonenHOCHSEC        Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co
11.02.2020Item 5.02 — Abgang SchlüsselpersonenHOCHSEC          Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Stammdaten

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Unternehmen & Branche

NameABBOTT LABORATORIES
TickerABT
CIK0000001800
BoerseUS
SektorHealthcare
IndustrieMedical - Devices
SIC2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP028241000
ISINUS0282410002
TypCommon Stock
Marktkapitalisierung159,66 Mrd. USD
Beta0,78
Dividendenrendite2,44 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

PeriodeFilingUmsatzNettoergebnisEPSAktivaEigenkapital
2025-12-3110-K44,328,000,0006,524,000,0003.7286,713,000,00052,130,000,000
2025-09-3010-Q11,369,000,0001,644,000,0000.9484,181,000,00050,954,000,000
2025-06-3010-Q11,142,000,0001,779,000,0001.0183,999,000,00050,565,000,000
2025-03-3110-Q10,358,000,0001,325,000,0000.7681,448,000,00048,811,000,000
2024-12-3110-K41,950,000,00013,402,000,0007.6481,414,000,00047,664,000,000
2024-09-3010-Q10,635,000,0001,646,000,0000.9474,356,000,00039,796,000,000
2024-06-3010-Q10,377,000,0001,302,000,0000.7473,017,000,00039,318,000,000
2024-03-3110-Q9,964,000,0001,225,000,0000.7072,467,000,00038,810,000,000
2023-12-3110-K40,109,000,0005,723,000,0003.2673,214,000,00038,603,000,000
2023-09-3010-Q10,143,000,0001,436,000,0000.8272,090,000,00037,481,000,000
2023-06-3010-Q9,978,000,0001,375,000,0000.7873,354,000,00037,174,000,000
2023-03-3110-Q9,747,000,0001,318,000,0000.7573,794,000,00037,010,000,000
2022-12-3110-K43,653,000,0006,933,000,0003.9174,438,000,00036,686,000,000
2022-09-3010-Q10,410,000,0001,435,000,0000.8172,801,000,00035,675,000,000
2022-06-3010-Q11,257,000,0002,018,000,0001.1474,202,000,00036,490,000,000
2022-03-3110-Q11,895,000,0002,447,000,0001.3774,007,000,00035,399,000,000
2021-12-3110-K43,075,000,0007,071,000,0003.9475,196,000,00035,802,000,000
2021-09-3010-Q10,928,000,0002,100,000,0001.1773,795,000,00034,422,000,000
2021-06-3010-Q10,223,000,0001,189,000,0000.6673,269,000,00033,800,000,000
2021-03-3110-Q10,456,000,0001,793,000,0001.0072,785,000,00033,562,000,000

Fondsaktivität (Vorquartalsvergleich)

FondsAktuell (Stk)Vorquartal (Stk)Veränderung (Stk)Wert (USD)StatusΔTrend
Ironwood Investment Counsel, LLC12,295012,2951,540,552Neu+100,0%

Insider-Transaktionen (12 Monate)

DatumInsiderRolleTypStückzahlKursWert (USD)ΔTrend
2026-04-27STARKS DANIEL JDirectorOpen Market Purchase10,00092.65926,537.00+216,1%
2026-04-23Boudreau Philip POfficer, EVP AND CFOOpen Market Purchase2,20091.50201,300.00+47,0%
2026-03-02Salvadori Daniel Gesua SiveOfficer, EVP AND GROUP PRESIDENTOpen Market Sale-885115.58-102,288.30-23,9%
2026-03-02Cushman Elizabeth C.Officer, EVP, GC AND SECRETARYOpen Market Sale-263115.58-30,397.54-7,1%
2026-03-02MCCOY JOHN A. JR.Officer, VICE PRESIDENT AND CONTROLLEROpen Market Sale-585115.58-67,614.30-15,8%
2026-03-02Moreland Mary KOfficer, EXECUTIVE VICE PRESIDENTOpen Market Sale-613115.58-70,850.54-16,5%
2026-03-02Shroff EricOfficer, Senior Vice PresidentOpen Market Sale-709115.58-81,946.22-19,1%
2026-03-02Morrone Louis H.Officer, EXECUTIVE VICE PRESIDENTOpen Market Sale-1,144115.58-132,223.52-30,8%
2026-02-04STARKS DANIEL JDirectorOpen Market Purchase4,967109.14542,092.42+126,5%
2026-02-04STARKS DANIEL JDirectorOpen Market Purchase5,033108.33545,238.98+127,2%
2026-01-23Ford Robert BDirector, Officer, CHAIRMAN AND CEOOpen Market Purchase18,800107.132,013,966.92+469,8%
2025-11-25Shroff EricOfficer, Senior Vice PresidentOpen Market Sale-1,586128.02-203,042.57-47,4%
2025-08-08Boudreau Philip POfficer, EVP AND CFOOpen Market Sale-5,550134.55-746,758.05-174,2%
2025-04-30Blount Sally E.DirectorOpen Market Sale-2,600129.66-337,116.00-78,6%

Top-Fondshalter

Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.

FondsAnteileWert (USD)Anteil (%)
Ironwood Investment Counsel, LLC12,2951,540,552100.00

Hinweis

Erweitert ×